The synthesis of a novel binaphthyl-based cyclic peptoid with anti-bacterial activityElectronic supplementary information (ESI) available: ESMS data. See http://www.rsc.org/suppdata/nj/b2/b205894b/
作者:John B. Bremner、Jonathan A. Coates、Daniel R. Coghlan、Dorothy M. David、Paul A. Keller、Stephen G. Pyne
DOI:10.1039/b205894b
日期:2002.10.30
The novel cyclic peptoid 1, based upon a 1,1′-binaphthyl scaffold and a bridging tripeptide moiety, was synthesised utilising a ring-closing metathesis reaction, and was shown to possess anti-bacterial properties.
New cyclic peptides via ring-closing metathesis reactions and their anti-bacterial activities
作者:Timothy P. Boyle、John B. Bremner、Jonathan Coates、John Deadman、Paul A. Keller、Stephen G. Pyne、David I. Rhodes
DOI:10.1016/j.tet.2008.09.031
日期:2008.12
As part of a program investigating cyclic peptides with an internal aromatic hydrophobic scaffold as potential novel anti-bacterial agents, we explored the synthesis of simple tyrosine-based systems. These were prepared via key intermediates containing internal allylglycine and allyltyrosine residues for subsequent ring-closingmetathesis reactions. Although the resulting anti-bacterial activity against
The present invention provides a compound of formula (I), (II), (III) and (IV) as defined herein and pharmaceutically acceptable derivatives thereof. The present invention further provides use of the compounds of the present invention in the treatment of bacterial infection and in the treatment of HIV infection. Also provided are pharmaceutical compositions comprising the compounds of the present invention.
The present invention provides a compound of formula I, II, III and IV as defined herein and pharmaceutically acceptable derivatives thereof. The present invention further provides use of the compounds of the present invention in the treatment of bacterial infection and in the treatment of HIV infection. Also provided are pharmaceutical compositions comprising the compounds of the present invention.
The invention relates to new peptoid compounds of formula (I), as well as their use in the treatment of bacterial infections, such as those caused by vancomycin resistant microorganisms, and to compositions thereof.